Advertisement
Screener

Traws Pharma, Inc. (TRAW) Cash Flow Breakdown

1.8 / 5 stars · 32/91 Roast Me

Traws Pharma, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Traws Pharma, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $18.18M went out.
  • Fiscal year ended 2025-12-31: from investing, $2.58M went out.
  • Fiscal year ended 2025-12-31: from financing, $3.20M came in.
  • Fiscal year ended 2025-12-31: change in cash, $17.52M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingDebt paid backNew debtNew shares soldNot split outChange in cash
2025-12-31-$18.18M-$2.58M$5.58M-$2.38M*-$17.52M
2024-12-31-$29.79M-$3.65M$33.98M*$517.00K
2023-12-31-$17.93M-$14.00K-$17.94M
2022-12-31-$16.29M-$16.31M
2021-12-31-$19.49M$55.04M$519.00K*$36.05M
2020-12-31-$23.07M-$15.00K$9.06M$10.29M*-$3.70M
2019-12-31-$20.83M-$55.00K$21.76M$4.89M*$5.76M
2018-12-31-$22.70M$35.07M$589.00K*$12.95M
2017-12-31-$23.82M$6.36M*-$17.43M
2016-12-31-$15.81M$3.00K$17.42M*$1.60M
2015-12-31-$31.24M$7.46M-$23.78M
2014-12-31-$57.65M$39.77M$963.00K$500.00K*-$16.43M
2013-12-31-$61.38M-$40.60M$157.00K$80.31M*
2012-12-31$1.63M-$279.00K$25.82M$165.00K$51.47M*
2011-12-31-$14.17M-$241.00K-$917.00K$620.00K$154.00K$9.93M*

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew debtNew shares soldNot split outChange in cash
2026-06-30-$7.50M*$120.00K*$9.27M*
2026-03-31-$2.58M$1.90M-$687.00K
2025-12-31-$2.76M*$0.00*$2.09M*
2025-09-30-$4.01M*$116.00K*
2025-06-30-$5.98M*$3.26M*
2025-03-31-$5.44M$122.00K-$5.40M
2024-12-31-$4.04M*$0.00*$19.98M*
2024-09-30-$11.48M*$0.00*$0.00*
2024-06-30-$9.85M*
2024-03-31-$4.42M-$4.43M
2023-12-31-$4.43M*$0.00*
2023-09-30-$4.47M*
2023-06-30-$4.49M*
2023-03-31-$4.54M-$4.54M
2022-12-31-$3.88M*
2022-09-30-$3.90M*
2022-06-30-$4.21M*
2022-03-31-$4.30M-$4.30M
2021-12-31-$4.26M*-$50.00K*
2021-09-30-$4.27M*$19.94M*
2021-06-30-$4.31M*$0.00*
2021-03-31-$6.65M$35.15M$28.98M
2020-12-31-$5.47M*$0.00*$0.00*
2020-09-30-$5.76M*$0.00*$0.00*$2.72M*
2020-06-30-$5.38M*$0.00*$1.58M*
2020-03-31-$6.46M$9.06M$5.72M*$8.31M
2019-12-31-$5.36M*$1.00K*$18.40M*$4.86M*
2019-09-30-$3.96M*$2.97M*
2019-06-30-$4.91M*
2019-03-31-$6.60M-$6.57M
2018-12-31-$5.41M*
2018-09-30-$7.15M*
2018-06-30-$4.62M*$26.92M*
2018-03-31-$5.51M$8.74M*$3.24M
2017-12-31-$4.67M*$1.04M*-$3.63M*
2017-09-30-$7.40M*-$7.39M*
2017-06-30-$5.69M*$5.28M*-$400.00K*
2017-03-31-$6.06M-$6.01M
2016-12-31-$4.36M*$0.00*-$4.38M*
2016-09-30-$2.86M*$15.81M*$12.96M*
2016-06-30-$4.01M*-$2.00K*-$4.02M*
2016-03-31-$4.58M$1.61M-$2.96M
2015-12-31-$5.04M*$2.65M*-$2.40M*
2015-09-30-$7.87M*$4.71M*-$3.16M*
2015-06-30-$8.47M*-$8.34M*
2015-03-31-$9.85M-$9.88M
2014-12-31-$14.27M*$14.99M*$15.00K*$500.00K*$1.23M*
2014-09-30-$13.19M*$0.00*$50.00K*-$13.15M*
2014-06-30-$14.02M*$14.85M*$45.00K*
2014-03-31-$16.16M$9.93M$853.00K
2013-12-31-$17.13M*-$94.00K*$106.00K*
2013-09-30-$14.37M*-$40.03M*$45.00K*$79.81M*
2013-06-30-$15.94M*-$189.00K*$0.00*
2013-03-31-$13.95M-$284.00K$6.00K
2012-12-31-$27.72M*-$148.00K*$0.00*$140.00K*$1.11M*
2012-09-30$41.60M*-$125.00K*$16.34M*$16.00K*$47.80M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Alzamend Neuro, Inc. (ALZN)United States$0.009B
Imunon, Inc. (IMNN)United States$0.008B-0.56
SOLIGENIX, INC. (SNGX)United States$0.008B
FibroBiologics, Inc. (FBLG)United States$0.009B-0.27
EXICURE, INC. (XCUR)United States$0.008B-1.54
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Aprea Therapeutics, Inc. (APRE)United States$0.010B-0.78
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B